Background. Prevalence and incidence of drug eruptions vary around the world and are influenced by some key factors including\nHIV infection. Objective. This study aimed to find the peculiarities of drug eruptions in people living with HIV (PLHIV) and on\nantiretroviral therapy (ART). Methods. This was a retrospective cross-sectional study including ART-taking PLHIV, aged 15+ years,\nfollowed up between January 2010 and December 2014 at the day-care unit of the Yaound�´e Central Hospital, and who presented\nwith drug eruptions after ART initiation. Results. Of 6,829 ART-experiencing PLHIV, 41 presented with drug eruptions, giving a\nprevalence of 0.6%.TheM/F sex ratio equaled 0.17.Themean age was 41.07 �± 11.36 years. Benign drug eruptions accounted for 83.3%.\nMilder forms were essentially maculopapular exanthema (36.6%), fixed pigmented erythema (7.3%), and urticaria (4.9%). Severe\nforms were represented by multiform erythema (4.9%), toxic epidermal necrolysis (2.4%), and drug hypersensitivity syndrome\n(2.4%). The Zidovudine + Lamivudine + Efavirenz ART-protocol was received by 48.8% of patients and 69% of patients were\nreceivingCotrimoxazole prophylaxis.Nevirapine, Efavirenz, Zidovudine, andCotrimoxazolewere suspected as the potential causes\nin 43.7%, 4.8%, 2.4%, and 26.8% of cases, respectively. Conclusion. Drug eruptions seem infrequent among ART-exposed HIV\ninfected adult Cameroonians.
Loading....